Bringing Immunofocusing into Focus

Overview

Journal NPJ Vaccines

Date 2024 Jan 9

PMID 38195562

Authors

Sriharshita Musunuri

Payton A B Weidenbacher

Peter S Kim

Affiliations

Soon will be listed here.

Abstract

Immunofocusing is a strategy to create immunogens that redirect humoral immune responses towards a targeted epitope and away from non-desirable epitopes. Immunofocusing methods often aim to develop "universal" vaccines that provide broad protection against highly variant viruses such as influenza virus, human immunodeficiency virus (HIV-1), and most recently, severe acute respiratory syndrome coronavirus (SARS-CoV-2). We use existing examples to illustrate five main immunofocusing strategies-cross-strain boosting, mosaic display, protein dissection, epitope scaffolding, and epitope masking. We also discuss obstacles for immunofocusing like immune imprinting. A thorough understanding, advancement, and application of the methods we outline here will enable the design of high-resolution vaccines that protect against future viral outbreaks.

Citing Articles

Structural characterization of influenza group 1 chimeric hemagglutinins as broad vaccine immunogens.

Nguyen Y, Zhu X, Han J, Rodriguez A, Sun W, Yu W Proc Natl Acad Sci U S A. 2025; 122(7):e2416628122.

PMID: 39937865 PMC: 11848309. DOI: 10.1073/pnas.2416628122.

RBD-displaying OMV nanovaccine boosts immunity against SARS-CoV-2.

Feng R, Xue R, Liu C, Li G, Deng Y, Jin Z J Nanobiotechnology. 2025; 23(1):97.

PMID: 39923096 PMC: 11807311. DOI: 10.1186/s12951-025-03191-7.

MERS-CoV spike vaccine-induced N-terminal domain-specific antibodies are more protective than receptor binding domain-specific antibodies.

Abiona O, Wang N, Leist S, Schafer A, Cockrell A, Wang L iScience. 2025; 28(2):111632.

PMID: 39898019 PMC: 11783452. DOI: 10.1016/j.isci.2024.111632.

Rethinking Optimal Immunogens to Face SARS-CoV-2 Evolution Through Vaccination.

Blanco J, Trinite B, Puig-Barbera J Influenza Other Respir Viruses. 2025; 19(1):e70076.

PMID: 39871737 PMC: 11773156. DOI: 10.1111/irv.70076.

Advances in protein subunit vaccines against H1N1/09 influenza.

Zhang Y, Gao J, Xu W, Huo X, Wang J, Xu Y Front Immunol. 2024; 15:1499754.

PMID: 39650643 PMC: 11621219. DOI: 10.3389/fimmu.2024.1499754.

References

Jardine J, Julien J, Menis S, Ota T, Kalyuzhniy O, McGuire A . Rational HIV immunogen design to target specific germline B cell receptors. Science. 2013; 340(6133):711-6. PMC: 3689846. DOI: 10.1126/science.1234150. View

Sette A, Saphire E . Inducing broad-based immunity against viruses with pandemic potential. Immunity. 2022; 55(5):738-748. PMC: 10286218. DOI: 10.1016/j.immuni.2022.04.010. View

Havenar-Daughton C, Abbott R, Schief W, Crotty S . When designing vaccines, consider the starting material: the human B cell repertoire. Curr Opin Immunol. 2018; 53:209-216. PMC: 6148213. DOI: 10.1016/j.coi.2018.08.002. View

Lee J, Sutton H, Cottrell C, Phung I, Ozorowski G, Sewall L . Long-primed germinal centres with enduring affinity maturation and clonal migration. Nature. 2022; 609(7929):998-1004. PMC: 9491273. DOI: 10.1038/s41586-022-05216-9. View

Abuchowski A, van Es T, Palczuk N, DAVIS F . Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem. 1977; 252(11):3578-81. View

Kirkpatrick E, Qiu X, Wilson P, Bahl J, Krammer F . The influenza virus hemagglutinin head evolves faster than the stalk domain. Sci Rep. 2018; 8(1):10432. PMC: 6041311. DOI: 10.1038/s41598-018-28706-1. View

Garrity R, Rimmelzwaan G, Minassian A, Tsai W, Lin G, de Jong J . Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol. 1997; 159(1):279-89. View

Chiesa M, Martensen P, Simmons C, Porakishvili N, Justesen J, Dougan G . Refocusing of B-cell responses following a single amino acid substitution in an antigen. Immunology. 2001; 103(2):172-8. PMC: 1783232. DOI: 10.1046/j.1365-2567.2001.01242.x. View

Lin Z, Akin H, Rao R, Hie B, Zhu Z, Lu W . Evolutionary-scale prediction of atomic-level protein structure with a language model. Science. 2023; 379(6637):1123-1130. DOI: 10.1126/science.ade2574. View

10.

Cohen A, van Doremalen N, Greaney A, Andersen H, Sharma A, Starr T . Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science. 2022; 377(6606):eabq0839. PMC: 9273039. DOI: 10.1126/science.abq0839. View

11.

Pulendran B, Arunachalam P, OHagan D . Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021; 20(6):454-475. PMC: 8023785. DOI: 10.1038/s41573-021-00163-y. View

12.

Jegaskanda S, Andrews S, Wheatley A, Yewdell J, McDermott A, Subbarao K . Hemagglutinin head-specific responses dominate over stem-specific responses following prime boost with mismatched vaccines. JCI Insight. 2019; 4(22). PMC: 6948858. DOI: 10.1172/jci.insight.129035. View

13.

Shrock E, Timms R, Kula T, Mena E, West Jr A, Guo R . Germline-encoded amino acid-binding motifs drive immunodominant public antibody responses. Science. 2023; 380(6640):eadc9498. PMC: 10273302. DOI: 10.1126/science.adc9498. View

14.

Nachbagauer R, Feser J, Naficy A, Bernstein D, Guptill J, Walter E . A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat Med. 2020; 27(1):106-114. DOI: 10.1038/s41591-020-1118-7. View

15.

Caradonna T, Schmidt A . Protein engineering strategies for rational immunogen design. NPJ Vaccines. 2021; 6(1):154. PMC: 8683408. DOI: 10.1038/s41541-021-00417-1. View

16.

Walls A, Fiala B, Schafer A, Wrenn S, Pham M, Murphy M . Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Cell. 2020; 183(5):1367-1382.e17. PMC: 7604136. DOI: 10.1016/j.cell.2020.10.043. View

17.

Li Y, Cleveland B, Klots I, Travis B, Richardson B, Anderson D . Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol. 2007; 82(2):638-51. PMC: 2224603. DOI: 10.1128/JVI.01691-07. View

18.

Castro K, Scheck A, Xiao S, Correia B . Computational design of vaccine immunogens. Curr Opin Biotechnol. 2022; 78:102821. DOI: 10.1016/j.copbio.2022.102821. View

19.

Weidenbacher P, Kim P . Protect, modify, deprotect (PMD): A strategy for creating vaccines to elicit antibodies targeting a specific epitope. Proc Natl Acad Sci U S A. 2019; 116(20):9947-9952. PMC: 6525525. DOI: 10.1073/pnas.1822062116. View

20.

Hershfield M . PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin Immunol Immunopathol. 1995; 76(3 Pt 2):S228-32. DOI: 10.1016/s0090-1229(95)90306-2. View